MPHARM ALLIANCE LTD

Company Registration Number:
13209249 (England and Wales)

Unaudited abridged accounts for the year ended 29 February 2024

Period of accounts

Start date: 01 March 2023

End date: 29 February 2024

MPHARM ALLIANCE LTD

Contents of the Financial Statements

for the Period Ended 29 February 2024

Company Information - 3
Balance sheet - 4
Additional notes - 6
Balance sheet notes - 9

MPHARM ALLIANCE LTD

Company Information

for the Period Ended 29 February 2024




Director: M A Afzal
Registered office: 2a Mayfield Avenue
King Cross
Halifax
GBR
HX1 3XE
Company Registration Number: 13209249 (England and Wales)

MPHARM ALLIANCE LTD

Balance sheet

As at 29 February 2024


Notes

2024
£

2023
£
Fixed assets
Tangible assets: 4 186,375 187,500
Total fixed assets: 186,375 187,500
Current assets
Cash at bank and in hand: 11,692 10,636
Total current assets: 11,692 10,636
Creditors: amounts falling due within one year: ( 17,495 ) ( 41,797 )
Net current assets (liabilities): ( 5,803 ) ( 31,161 )
Total assets less current liabilities: 180,572 156,339
Creditors: amounts falling due after more than one year: ( 105,606 ) ( 104,357 )
Provision for liabilities: ( 2,583 ) ( 2,654 )
Total net assets (liabilities): 72,383 49,328

The notes form part of these financial statements

MPHARM ALLIANCE LTD

Balance sheet continued

As at 29 February 2024


Notes

2024
£

2023
£
Capital and reserves
Called up share capital: 100 100
Revaluation reserve: 12,219
Profit and loss account: 72,283 37,009
Shareholders funds: 72,383 49,328

For the year ending 29 February 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 23 November 2024
And Signed On Behalf Of The Board By:

Name: M A Afzal
Status: Director

The notes form part of these financial statements

MPHARM ALLIANCE LTD

Notes to the Financial Statements

for the Period Ended 29 February 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

MPHARM ALLIANCE LTD

Notes to the Financial Statements

for the Period Ended 29 February 2024

  • 2. Employees


    2024

    2023
    Average number of employees during the period 0 0

MPHARM ALLIANCE LTD

Notes to the Financial Statements

for the Period Ended 29 February 2024

  • 3. Off balance sheet disclosure

    No

MPHARM ALLIANCE LTD

Notes to the Financial Statements

for the Period Ended 29 February 2024

4. Tangible Assets

Total
Cost £
At 01 March 2023 189,500
Additions -
Disposals -
Revaluations -
Transfers -
At 29 February 2024 189,500
Depreciation
At 01 March 2023 2,000
Charge for year 1,125
On disposals -
Other adjustments -
At 29 February 2024 3,125
Net book value
At 29 February 2024 186,375
At 28 February 2023 187,500